...
首页> 外文期刊>Journal of Pathology: Journal of the Pathological Society of Great Britain and Ireland >Cytotoxic protein expression in natural killer cell lymphomas and in alpha beta and gamma delta peripheral T-cell lymphomas.
【24h】

Cytotoxic protein expression in natural killer cell lymphomas and in alpha beta and gamma delta peripheral T-cell lymphomas.

机译:在自然杀伤细胞淋巴瘤和alpha beta和γδ外周血T细胞淋巴瘤中的细胞毒性蛋白表达。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Lymphomas with T-cell phenotype represent a heterogeneous group of diseases differing in histopathology, tumour site, and cell origin. They include peripheral T-cell lymphomas (PTCLs) derived from alpha beta cells, but also some recently recognized entities such as gamma delta, hepatosplenic lymphomas and natural killer (NK) cell lymphomas. Only a few studies have investigated the possibility that at least some PTCLs could be derived from lymphocytes with cytotoxic potential. In order to investigate this possibility, 60 cases of PTCL, including 27 cases expressing the alpha beta T-cell receptor (TCR alpha beta), 15 TCR gamma delta cases and 18 cases expressing neither TCR (TCR silent), as well as 14 cases of NK-cell lymphomas, were studied by immunohistochemistry for the expression of TIA-1, perforin, and granzyme B proteins. Expression of TIA-1 is characteristic of cytotoxic cells regardless of their activation status, whereas expression of perforin and granzymes is highly increased in activated cytotoxic cells and correlates with the induction of cytolytic activity. All NK-cell lymphomas (11 sinonasal, three systemic cases) expressed TIA-1, perforin, and granzyme B in most tumour cells. All gamma delta PTCLs (15 cases) expressed TIA-1 protein in most tumour cells, with a different cytotoxic antigen profile in hepatosplenic gamma delta PTCL (TIA-1+, perforin-, granzyme B-) and in non-hepatosplenic gamma delta PTCLs (three nasal, one skin, one lung), the latter expressing the three cytotoxic proteins. Of the 45 cases of alpha beta and TCR silent PTCL, 15 (33 per cent) were considered to be derived from cytotoxic lymphocytes with expression of at least one cytotoxic protein (TIA-1, 15/45; perforin, 10/41; granzyme B, 14/38) in tumour cells. This cytotoxic protein expression appeared to be related to the site of localization, since 7/13 (54 per cent) extranodal and only 8/32 (25 per cent) nodal alpha beta and TCR silent PTCLs expressed TIA-1, and to histology, since this pattern was observed in a proportion of anaplastic (6/8, 75 per cent) and pleomorphic (8/17, 47 per cent) lymphomas, but not in AILD-type NHL (0/16). Taken together, our data suggest that NK-cell lymphomas and non-hepatosplenic gamma delta PTCLs represent tumours of activated cytotoxic NK cells and gamma delta T cells, respectively; that hepatosplenic gamma delta PTCLs represent tumours of non-activated cytotoxic gamma delta T cells; and that a small proportion of alpha beta and TCR silent PTCLs, mostly extranodal cases, or nodal anaplastic lymphomas, represent tumours of cytotoxic T cells.
机译:具有T细胞表型的淋巴瘤代表了一组异质性疾病,它们在组织病理学,肿瘤部位和细胞起源方面有所不同。它们包括衍生自αβ细胞的外周T细胞淋巴瘤(PTCL),还包括一些最近公认的实体,例如γδ,肝脾淋巴瘤和自然杀伤(NK)细胞淋巴瘤。只有少数研究调查了至少一些PTCL可能源自具有细胞毒性潜能的淋巴细胞的可能性。为了调查这种可能性,共60例PTCL,包括27例表达αβT细胞受体(TCR alpha beta)的患者,15例TCRγδ患者和18例既不表达TCR的患者(TCR沉默),以及14例通过免疫组织化学研究了NK细胞淋巴瘤细胞的TIA-1,穿孔素和颗粒酶B蛋白的表达。 TIA-1的表达是细胞毒性细胞的特征,而与它们的活化状态无关,而穿孔素和颗粒酶的表达在活化的细胞毒性细胞中高度增加,并且与溶细胞活性的诱导相关。所有NK细胞淋巴瘤(11例鼻窦,三例全身性病例)在大多数肿瘤细胞中均表达TIA-1,穿孔素和颗粒酶B。所有γ-δPTCLs(15例)在大多数肿瘤细胞中表达TIA-1蛋白,在肝脾γ-PTCL(TIA-1 +,穿孔素-,颗粒酶B-)和非肝脾γ-PTCLs中具有不同的细胞毒性抗原谱。 (三鼻,一皮肤,一肺),后者表达三种细胞毒性蛋白。在45例alpha beta和TCR沉默PTCL病例中,有15例(33%)被认为是来自具有至少一种细胞毒性蛋白表达的细胞毒性淋巴细胞(TIA-1,15 / 45;穿孔素,10/41;粒酶) B,14/38)。这种细胞毒性蛋白的表达似乎与定位部位有关,因为7/13(54%)的结外和8/32(25%)的节点alpha beta和TCR沉默PTCL表达TIA-1,并且与组织学有关,因为这种模式在部分变性(6 / 8,75%)和多形性(8 / 17,47%)淋巴瘤中观察到,但在AILD型NHL(0/16)中观察不到。两者合计,我们的数据表明,NK细胞淋巴瘤和非肝脾伽马三角洲PTCL分别代表激活的细胞毒性NK细胞和伽马三角洲T细胞的肿瘤。肝脾伽马三角洲PTCL代表未激活的细胞毒性伽马三角洲T细胞肿瘤;而且一小部分的alpha beta和TCR沉默PTCL(大多数为结外病例或结节间变性淋巴瘤)代表了细胞毒性T细胞肿瘤。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号